Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer …
Background Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts
and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. …
and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. …
Abiraterone and olaparib for metastatic castration-resistant prostate cancer
…, G Procopio, J de Menezes, G Girotto, C Arslan… - NEJM …, 2022 - evidence.nejm.org
Background Preclinical studies and results of a phase 2 trial of abiraterone and olaparib
suggest a combined antitumor effect when the poly(adenosine diphosphate[ADP]-ribose) …
suggest a combined antitumor effect when the poly(adenosine diphosphate[ADP]-ribose) …
Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized …
…, Y Hu, Y Li, S Zhang, J Cui, N Kovalenko, C Arslan… - Jama, 2022 - jamanetwork.com
Importance Programmed cell death ligand 1 inhibitors combined with chemotherapy has
changed the approach to first-line treatment in patients with extensive-stage small cell lung …
changed the approach to first-line treatment in patients with extensive-stage small cell lung …
PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant …
…, J Janoski de Menezes, GC Girotto, C Arslan… - 2022 - ascopubs.org
11 Background: Preclinical studies have shown combined anti-tumor effect through
interactions between poly(adenosine diphosphate–ribose) polymerase and androgen receptor …
interactions between poly(adenosine diphosphate–ribose) polymerase and androgen receptor …
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a …
…, N Shore, G Procopio, JD Guedes, C Arslan… - The Lancet …, 2023 - thelancet.com
Background PROpel met its primary endpoint showing statistically significant improvement
in radiographic progression-free survival with olaparib plus abiraterone versus placebo plus …
in radiographic progression-free survival with olaparib plus abiraterone versus placebo plus …
Osteosclerosis due to endemic fluorosis
Endemic water borne fluorosis is a public health problem in Isparta, a city located in southern
Turkey. In order to investigate the association between osteosclerosis and fluorosis, we …
Turkey. In order to investigate the association between osteosclerosis and fluorosis, we …
Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature
C Arslan, E Sari, S Aksoy, K Altundag - Expert opinion on …, 2011 - Taylor & Francis
Importance of the field: Hormone and human epidermal growth factor receptor 2 (HER-2)
receptors are two important pharmaceutical targets that affect the survival of patients with …
receptors are two important pharmaceutical targets that affect the survival of patients with …
Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration …
…, M Oya, ND Shore, G Procopio, JDC Guedes, C Arslan… - 2023 - ascopubs.org
LBA16 Background: PROpel (NCT03732820) met its primary endpoint showing significant
investigator-assessed radiographic progression-free survival (rPFS) benefit for patients with …
investigator-assessed radiographic progression-free survival (rPFS) benefit for patients with …
The effect of long-term low-dose lead exposure on thyroid function in adolescents
…, MK Arslan, N Delibas, B Baykal, Ç Arslan… - Environmental …, 2006 - Elsevier
This study investigated blood lead (Pb-B) levels and Pb-B effects on thyroid functions in long-term
low-level-lead-exposed male adolescents who work as auto repairers. Pb-B and …
low-level-lead-exposed male adolescents who work as auto repairers. Pb-B and …
[HTML][HTML] Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY …
…, A Stradella, CS Huang, S Aksoy, C Arslan… - European Journal of …, 2021 - Elsevier
Background In the phase III OlympiAD trial, olaparib significantly increased progression-free
survival (PFS) compared with chemotherapy of physician's choice in patients with germline …
survival (PFS) compared with chemotherapy of physician's choice in patients with germline …
